StephenL.HuhnMD

Research • San Diego, CA

Chief Medical Officer and Senior Vice President Clinical Development PIpeline Therapeutics

Join to view full profile

Dr. Huhn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huhn's full profile

Already have an account?

Office
10578 Science Center Dr
San Diego, CA 92121

Education & Training

University of MarylandResidency, Neurological Surgery, 1988 - 1993
University of Maryland Medical Center Midtown CampusInternship, Transitional Year, 1987 - 1988
University of Arizona College of MedicineClass of 1987

Certifications & Licensure

CA State Medical License 1993 - 2025
American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

Fellow American Academy of Pediatrics
Fellow (FACS) American College of Surgeons
Fellow (FAANS) American Association of Neurological Surgeons

Clinical Trials

Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects Start of enrollment: 2009 Nov 01
Completed
Phase 1
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury Start of enrollment: 2011 Mar 01
Completed
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers Start of enrollment: 2018 Mar 30
Completed
Phase 1
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss Start of enrollment: 2020 Oct 15
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

33 citations
Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease.
Nalin Gupta, Roland G. Henry, Sang-Mo Kang, Jonathan B. Strober, Daniel A. Lim
Stem Cell Reports. 2019-08-13
Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease.
Nalin Gupta, Roland G Henry, Sang-Mo Kang, Jonathan Strober, Daniel A Lim
Stem cell reports. 2019-08-06
10 citations
Subretinal Transplantation of Human Central Nervous System Stem Cells Stimulates Controlled Proliferation of Endogenous Retinal Pigment Epithelium.
Trevor J. McGill, Linda Osborne, Bin Lu, Jonathan Stoddard, Stephen L. Huhn
Translational Vision Science & Technology. 2019-05-01

Press Mentions

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple SclerosisMarch 28th, 2022
Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple SclerosisMarch 10th, 2022
Pipeline Testing PIPE-307 Remyelinating Compound in Healthy VolunteersMarch 9th, 2021
Join now to see all

Professional Memberships

Congress of Neurological Surgeons - CNS
Member
American Association of Neurological Surgeons - AANS
Fellow
American College of Surgeons - ACS
Member